Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San Diego–based company plans to make the CGM available for people over the age of 18 with diabetes on Dec. 1. Initially, the company plans to make the sensor available for users […]
Diabetes
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer. The continuous glucose monitor (CGM)-based offering received clearance for adults with type 2 diabetes on glargine U-100 long-acting insulin therapy. San Diego-based Dexcom says it marks the first and only CGM-integrated basal dosing optimizer cleared for type 2 diabetes. […]
Modular Medical submits next-gen insulin pump to FDA, expects 2026 launch
Modular Medical (Nasdaq:MODD) announced that it has submitted its next-generation Pivot insulin pump to the FDA for clearance. Modular Medical’s current pump, the MODD1, won FDA clearance nearly a year ago. It has microfluidics technology that allows for the low-cost pumping of insulin. The company announced earlier this year that it began converting its manufacturing line to […]
Medtronic Diabetes to submit patch pump to FDA by fall 2026, separation remains on track
Medtronic officials today said the planned separation of its Diabetes business (MiniMed) remains on track, with future offerings also on the horizon. On the company’s second-quarter earnings call, CFO Thierry Piéton outlined the expected timelines for the Diabetes business, following another quarter of significant growth. Global Diabetes revenues grew 10.3% year over year, despite a […]
Embecta expands partnership with Direct Relief to support diabetes initiatives on World Diabetes Day
Embecta (Nasdaq:EMBC) today announced an expansion of its partnership with Direct Relief to mark World Diabetes Day. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness […]
What diabetes tech companies are doing on World Diabetes Day 2025
Once again, World Diabetes Day, celebrated on Nov. 14 every year, has come around, highlighting new initiatives in the diabetes tech space. The date marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Dexcom unveils new advocates to support World Diabetes Day campaign
Dexcom (NSDQ:DXCM) today announced 16 new advocates representing people with diabetes as part of its World Diabetes Day campaign. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National […]
Renu MedTech introduces tubeless insulin patch pump in India
Renu MedTech today unveiled InsuPatch, its tubeless insulin patch pump designed specifically for advancing diabetes care in India. On LinkedIn, the Pune, India-based company labeled InsuPatch “India’s first tubeless, affordable, patch-style insulin infusion pump.” “Diabetes touches millions of lives across India — shaping routines, emotions, families, and futures,” the company wrote. “For individuals who depend […]
ViCentra highlights diabetes in the workplace on World Diabetes Day
ViCentra today shared its own employees’ stories to highlight diabetes in the workplace on World Diabetes Day. Today, Nov. 14, is World Diabetes Day, which marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. It also lands during the American Diabetes Association’s National Diabetes Awareness Month. […]
Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
Glucotrack (Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE. The company said in August that it expected a fourth-quarter investigational device exemption (IDE) submission for the long-term implantable continuous blood glucose monitor (CBGM). However, it says today that it anticipates a submission in […]
